Asymptomatic, Enlarging Plaque: Your Dx?

News
Poll

This annular violaceous plaque, which had been present for a few months, was unresponsive to treatment for tinea corporis with topical antifungals. Which of the following statements is true?

This annular violaceous plaque, which had been present for a few months, was unresponsive to treatment for tinea corporis with topical antifungals.

Which of the following statements is true?

A. The absence of epidermal scaling argues against tinea corporis.
B. Lesion location and appearance strongly suggest granuloma annulare.
C. The patient's age also suggests granuloma annulare.
D. Dyslipidemia is positively associated with granuloma annulare.
E. Granuloma annulare is often self-limited, but topical steroids may hasten resolution.
F. All of the above are true.

Newsletter

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!
Related Content
Dupilumab Sustains Long-Term Reduction of S. aureus in People with AD: Daily Dose / image credit: ©New Africa/AdobeStock

Dupilumab Sustains Long-Term Reduction of S. aureus in People with AD: Daily Dose

Sydney Jennings
July 16th 2025
Article

Your daily dose of the clinical news you may have missed.

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment

Sydney Jennings
July 8th 2025
Podcast

Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.

©Apogee Therapeutics

Apogee Hopes Raised by Phase 2 Data for APG777 to be a Best-In-Class for Atopic Dermatitis

Grace Halsey
July 7th 2025
Article

The investigational IL-13 inhibitor showed topline EASI-75 of 66.9% and reduced injection frequency in part A of the APEX phase 2 clinical trial.

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

Sydney Jennings
May 7th 2025
Podcast

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

Roflumilast Cream 0.15% Receives Strong Recommendation for Atopic Dermatitis in AAD Guideline Update / image credit ©Arcutis Biotherapeutics

Roflumilast Cream 0.15% Receives Strong Recommendation for Atopic Dermatitis in AAD Guideline Update

Grace Halsey
June 26th 2025
Article

Roflumilast 0.15% is the only 1 of 4 newly evaluated branded topical therapies to receive the Academy's strong recommendation for AD management in adults.

Investigational Respegaldesleukin Drives Early EASI Improvement and Symptom Relief in Adults with Moderate-to-Severe Atopic Dermatitis

Investigational Rezpegaldesleukin Drives Early EASI Improvement and Symptom Relief in Adults with Moderate-to-Severe Atopic Dermatitis

Grace Halsey
June 25th 2025
Article

In the phase 2b trial, the IL-2 pathway agonist and Treg proliferator demonstrated a strong dose-dependent biological response across 3 treatment arms vs placebo.

© 2025 MJH Life Sciences

All rights reserved.